Keenova doses first patient in Phase 3 XIAFLEX hammer toe trial
MNK’s Keenova advances its podiatry pipeline by dosing the first patient in a Phase 3 trial of XIAFLEX (collagenase clostridium histolyticum) for hammer toe.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.